A new pancreatic cancer treatment was approved. Does that change whether you can be operated on?

A new medicine, daraxonrasib (Rasonque), has been approved in the United States for metastatic pancreatic cancer after chemotherapy. It is an important development. It is not a surgical treatment, it is not available everywhere, and it does not by itself make a tumour operable. What has not changed: for many patients told “inoperable”, the deciding factor is whether a high-volume surgical team re-reads the imaging.

The new medicine is approved for metastatic disease — cancer that has spread — and for patients who have already had chemotherapy. We say this plainly because the honest answer is the useful one. If your question is whether surgery is now possible for you, that is answered by a specialist reviewing your current imaging, not by the drug news.

The newest post-operative options open only to patients whose tumour has been removed. The Phase 3 adjuvant RAS-inhibitor programme (RASolute 304) and the personalised mRNA neoantigen vaccine research both enrol patients after a resection. Being operated on is what keeps the next wave of options within reach — not out of it.

“Inoperable” is frequently a judgement about a particular surgical team’s capability, not a fixed fact about the tumour. Vascular involvement, response to chemotherapy, borderline-resectable anatomy and centre volume all change the answer. A surgeon who performs 600–800 pancreatic resections a year — including vascular resection and reconstruction on the hardest cases — draws the line of “inoperable” in a different place than a surgeon who performs twenty.

None of these automatically mean surgery is impossible. They mean surgery is not possible at that institution, with that surgeon, at this time.

Most tumours called “inoperable due to vascular involvement” are refused because removing them would require resecting and reconstructing the portal vein or the superior mesenteric artery.

Prof. Büchler developed and pioneered the Heidelberg Triangle technique for exactly this anatomy — vascular resection and reconstruction that allows complete tumour removal where major vessels are involved. This is not widely available: it needs both the surgical expertise and the institutional infrastructure to manage vascular reconstruction safely at high volume.

At our Pancreatic Cancer Center in Lisbon, this is routine. The 0.8% mortality rate reflects outcomes even on these most complex cases.

In pancreatic surgery, outcomes are directly correlated with surgical volume. The threshold for calling a case “inoperable” is drawn in a fundamentally different place at 20 operations a year versus 600–800.

If you have had one assessment, you have one data point. A second assessment at this volume level is a different data point entirely.